These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

333 related items for PubMed ID: 15450339

  • 1. Psoriasis and its treatment with infliximab-mediated tumor necrosis factor alpha blockade.
    Winterfield L, Menter A.
    Dermatol Clin; 2004 Oct; 22(4):437-47, ix. PubMed ID: 15450339
    [Abstract] [Full Text] [Related]

  • 2. [Infliximab].
    Herrera E, Habicheyn S.
    Actas Dermosifiliogr; 2008 Jul; 99 Suppl 4():7-13. PubMed ID: 19080986
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Infliximab for the treatment of psoriasis in Greece: 4 years of clinical experience at a single centre.
    Antoniou C, Stefanaki I, Stratigos A, Moustou E, Vergou T, Stavropoulos P, Avgerinou G, Rigopoulos D, Katsambas AD.
    Br J Dermatol; 2010 May; 162(5):1117-23. PubMed ID: 19906069
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. The treatment of psoriasis and psoriatic arthritis with etanercept: practical considerations on monotherapy, combination therapy, and safety.
    Yamauchi PS, Gindi V, Lowe NJ.
    Dermatol Clin; 2004 Oct; 22(4):449-59, ix. PubMed ID: 15450340
    [Abstract] [Full Text] [Related]

  • 11. [Infectious risk].
    Calabuig E, Salavert M.
    Actas Dermosifiliogr; 2008 Jul; 99 Suppl 4():14-22. PubMed ID: 19080987
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Infliximab monotherapy in psoriasis: a case of rapid clinical and histological response.
    Vincek V, Jacob SE, Nassiri M, Herbert LM, Nadji M, Kerdel FA.
    Int J Dermatol; 2004 Apr; 43(4):303-8. PubMed ID: 15090021
    [Abstract] [Full Text] [Related]

  • 14. Infliximab.
    Winterfield LS, Menter A.
    Dermatol Ther; 2004 Apr; 17(5):409-26. PubMed ID: 15379776
    [Abstract] [Full Text] [Related]

  • 15. Sustained effects of low dose infliximab in combination with methotrexate in the management of chronic recalcitrant psoriasis.
    Zargari O.
    Dermatol Online J; 2005 Dec 01; 11(3):21. PubMed ID: 16409917
    [Abstract] [Full Text] [Related]

  • 16. Infliximab treatment for psoriasis in 120 patients on therapy for a minimum of one year: a review.
    Kamili QU, Miner A, Hapa A, Menter A.
    J Drugs Dermatol; 2011 May 01; 10(5):539-44. PubMed ID: 21533302
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Current concepts and review of pimecrolimus in the treatment of psoriasis.
    Wolff K.
    Dermatol Clin; 2004 Oct 01; 22(4):461-5, ix-x. PubMed ID: 15450341
    [Abstract] [Full Text] [Related]

  • 20. Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: a double-blind placebo-controlled trial.
    Feldman SR, Gordon KB, Bala M, Evans R, Li S, Dooley LT, Guzzo C, Patel K, Menter A, Gottlieb AB.
    Br J Dermatol; 2005 May 01; 152(5):954-60. PubMed ID: 15888152
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.